openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) over potential Wrongdoing

An investigation on behalf of current long term investors in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares.

An investigation on behalf of current long term investors in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares.

An investigation was announced for current long-term investors in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) concerning potential breaches of fiduciary duties by certain directors and officers of Amylyx Pharmaceuticals, Inc.

Investors who are current long term investors in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: AMLX stocks follows a lawsuit filed against Amylyx Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: AMLX stocks, concerns whether certain Amylyx Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that the Defendants had overstated RELYVRIO's commercial prospects, that patients were discontinuing treatment with RELYVRIO after six months, that the rate at which new patients were starting treatment with RELYVRIO was decreasing, that accordingly, that the Defendants had also overstated RELYVRIO's prescription rate, that the Defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data, and that as a result, the Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) over potential Wrongdoing here

News-ID: 3644422 • Views:

More Releases from Shareholders Foundation, Inc.

Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (NYSE: TROX)
Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (N …
An investor, who purchased shares of Tronox Holdings plc (NYSE: TROX), filed a lawsuit over alleged violations of Federal Securities Laws by Tronox Holdings plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Tronox Holdings plc (NYSE: TROX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 3, 2025. NYSE: TROX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF)
Investigation announced for Investors in Petco Health and Wellness Company, Inc. …
An investigation was announced for current long-term investors in shares of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) concerning potential breaches of fiduciary duties by certain directors of Petco Health and Wellness Company, Inc. Investors who are current long term investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) over potential Wrongdoing
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) …
An investigation was announced for current long-term investors in shares of RxSight, Inc. (NASDAQ: RXST) concerning potential breaches of fiduciary duties by certain directors of RxSight, Inc. Investors who are current long term investors in RxSight, Inc. (NASDAQ: RXST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: RXST
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 2025
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 202 …
A deadline is coming up on October 3, 2025 in the lawsuit filed for certain investors of Tesla, Inc. (NASDAQ: TSLA) over alleged securities laws violations by Tesla, Inc. Investors who purchased shares of Tesla, Inc. (NASDAQ: TSLA) have certain options and there are strict and short deadlines running. Deadline: October 3, 2025. Tesla, Inc. (NASDAQ: TSLA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Amylyx

Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & Growth Drivers | Bi …
The latest report on the "Amyotrophic lateral Sclerosis Market" by Worldwide Market Reports delivers a comprehensive and detailed evaluation of global industry dynamics, uncovering the core trends that shape the competitive landscape. By analyzing key growth drivers, market constraints, emerging opportunities, and sector challenges, the study offers an extensive understanding of the market's behavior. This report is based on rigorously validated research methodologies, ensuring data precision and credibility. It explores
Amyotrophic Lateral Sclerosis Clinical Trials | A Drug Pipeline Analysis Report …
United States, Nevada, Las Vegas, DelveInsight's 'Amyotrophic Lateral Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Amyotrophic Lateral Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Amyotrophic Lateral Sclerosis pipeline domain. Request for a sample report @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report Over 100+ Amyotrophic Lateral
Amyotrophic Lateral Sclerosis Treatment Market is Booming with Strong Growth Pro …
Amyotrophic Lateral Sclerosis Treatment Market is the latest research study released by USD Analytics Market evaluating the market, size, share, sales, highlighting opportunities, risk analysis, and leveraging with strategic and tactical decision-making support. The factors that impact growth and rules concerning the use of information, the accessibility of dependable products in the market, and the enhancement of operational efficiency among players in Amyotrophic Lateral Sclerosis Treatment. Information on market development,
Deadline on April 9th coming up in Lawsuit for Investors who lost money with Amy …
A deadline is coming up on April 9, 2024 in the lawsuit filed for certain investors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). Investors who purchased shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) have certain options and there are strict and short deadlines running. Deadline: April 9, 2024. NASDAQ: AMLX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S. District
Lawsuit filed for Investors in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: A …
An investor, who purchased shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), filed a lawsuit over alleged violations of Federal Securities Laws by Amylyx Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) have certain options and for certain investors are short and strict deadlines running. Deadline: April 9, 2024. NASDAQ: AMLX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
AMX0035 (Relyvrio) for Amyotrophic Lateral Sclerosis: Market Size and Share Anal …
DelveInsight has released a comprehensive report titled "AMX0035 Market Forecast" offering a thorough examination and predictive insights into the AMX0035 market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of AMX0035 in the therapeutics landscape for Amyotrophic Lateral Sclerosis across the